180 Life Sciences (NASDAQ: ATNF)
, a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that board chairman Jagdeep Nanchahal will be presenting the keynote address at the upcoming British Society for Surgery of the Hand (“BSSH”) meeting. The meeting will be held on Thursday, Sept. 9, 2021, at 9 a.m. British Standard Time (4 a.m. ET). Nanchahal is a professor of hand, plastic and reconstructive surgery at the University of Oxford and chairman of the company’s Clinical Advisory Board. His presentation will include an overview of his extensive breakthrough scientific research in defining the molecular pathways of the fibrotic process in Dupuytren’s disease, which causes the fingers to curl irreversibly into the palm; he will also discuss potential therapeutic approaches. 180 Life Sciences’ CEO Dr. James Woody noted that the company was pleased Nanchahal could present his scientific work to colleagues who have extensive experience in treating patients with late-stage Dupuytren’s disease. “By systematically analyzing tissues normally discarded at the time of surgery, we were able to identify a potential therapeutic target and progress through to testing in patients with early-stage Dupuytren’s disease,” said 180 Life Sciences Clinical Advisory Board chairman Professor Jagdeep Nanchahal in the press release.
To view the full press release, visit https://ibn.fm/tmzSj
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com
NOTE TO INVESTORS:
The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.